STIRIPENTOL

Clinical Indication

For the treatment of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome). Treatment should be continued into adulthood if efficacy is observed.

Comments

Orange for NEW Patients (Historic patients to carry on with current arrangements)

Date of classification

January 2026

Orange

Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.